| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5919775 | GALDERMA LABS LP | Method for inhibiting expression of inducible nitric oxide synthase with tetracycline |
Aug, 2016
(7 years ago) | |
| US5789395 | GALDERMA LABS LP | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
Aug, 2016
(7 years ago) | |
| US10058564 | GALDERMA LABS LP | Methods of treating acne |
Apr, 2022
(2 years ago) | |
| US7232572 | GALDERMA LABS LP | Methods of treating rosacea |
Apr, 2022
(2 years ago) | |
| US9241946 | GALDERMA LABS LP | Methods of treating acne |
Apr, 2022
(2 years ago) | |
| US8603506 | GALDERMA LABS LP | Methods of treating acne |
Apr, 2022
(2 years ago) | |
| US7211267 | GALDERMA LABS LP | Methods of treating acne |
Apr, 2022
(2 years ago) | |
| US8394406 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(18 days ago) | |
| US8709478 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(18 days ago) | |
| US8394405 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(18 days ago) | |
| US8470364 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(18 days ago) | |
| US8206740 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Dec, 2025
(1 year, 7 months from now) | |
| US7749532 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Dec, 2027
(3 years from now) | |
Oracea is owned by Galderma Labs Lp.
Oracea contains Doxycycline.
Oracea has a total of 13 drug patents out of which 11 drug patents have expired.
Expired drug patents of Oracea are:
- US5919775
- US5789395
- US10058564
- US7232572
- US9241946
- US8603506
- US7211267
- US8394406
- US8709478
- US8394405
- US8470364
Oracea was authorised for market use on 26 May, 2006.
Oracea is available in capsule;oral dosage forms.
Oracea can be used as treatment of only inflammatory lesions (papules and pustules) of rosacea.
The generics of Oracea are possible to be released after 19 December, 2027.
Drugs and Companies using DOXYCYCLINE ingredient
Market Authorisation Date: 26 May, 2006
Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea
Dosage: CAPSULE;ORAL
ORACEA family patents
